Biggest News Aggregation in the World
📰 Practice Guideline News

Practice Guideline News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Practice Guideline. Real-time updates on events, politics, business and more.

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...
Czech Republic United States Parag Mahanti David Soergel Prnewswire Novartis Marianne Silkj

Novartis Pharma AG: Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs.
United States Sloan Simpson Nicole Zinsli Somm Lambers Heerspink Jonathan Graham Satoshi Sugimoto

Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2
United States Czech Republic Imke Kappes Marlena Abdinoor David Soergel Michael Meo

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science